linjc16/ctgov huggingface dataset:
Prognostic Nomogram of Extranodal NK/T-cell Lymphoma

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate prognostic factors for overall survival and explore risk progression-free survival in ENKTL, and establish a prognostic predictive nomogram for ENKTL patients.

Detailed Description
-----------------
This is a retrospective cohort study using anonymized information from patients with ENKTL. The following criteria are required: (1) Patients diagnosed with ENKTL between January 1, 2000 and August 31, 2020; (2) Patients older than 18 years. The pathology of initial diagnosis was reviewed by designated pathologists.

Official Title
-----------------
Prognostic Nomogram of Extranodal NK/T-cell Lymphoma: A Multi-center Retrospective Study

Conditions
-----------------
Extranodal NK/T-cell Lymphoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients newly diagnosed with ENKTL Patients diagnosed between January 1, 2000 and August 31, 2020 Patients older than 18 years Exclusion Criteria: Patients who did not have complete clinical information or immunohistochemistry, or who were lost follow-up immediately after treatment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Training cohort<br>Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020. | |
| Validation Cohort<br>Patients diagnosed with ENKTL, between January 1, 2000 and August 31, 2020. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Time between the date of diagnosis and any kinds of death | 5 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | Time between the date of diagnosis and any kinds of death or relapse/progression | 5 year |
Results of a Mobile Unicompartimental Knee Prosthesis

Study Overview
=================
Brief Summary
-----------------
The unicompartmental knee prosthesis has become a routine procedure. Survival rate of over 90% after 10 years are generally reported. However, complications and reoperation may still occur for many reasons, and some of them may be related to component design: loosening (tibial above), polyethylene wear, knee stiffness, ligamentous instability, etc ... . Therefore, new designs can, at least in theory, improve the results of conventional models. In this study, the investigators want to compare retrospectively data concerning survival rates of patients wearing unicompartmental knee prosthesis with mobile plate for over 10 years, with the ones published in the literature for conventional fixed-bearing prostheses and mobile-bearing prostheses

Official Title
-----------------
Survival Rates of Atients Wearing a Mobile Unicompartimental Knee Prosthesis for the Past 10 Years

Conditions
-----------------
Knee Replacement

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years Patients wearing unicompartmental knee prosthesis with mobile plate for over 10 years Exclusion Criteria: Patients under 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare retrospectively data concerning survival rates of patients wearingunicompartmental knee prosthesis with mobile plate for over 10 years, with the ones published in the literature for conventional fixed and mobile bearing prosthesis. |  | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Knee, Replacement, Mobile-bearing, unicompartmental prosthesis
The Correlation Between Ultrasonography Based Muscle Architecture Parameters and Voluntary Isometric Muscle Strength

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to investigate potential relations of ultrasound-based muscle architecture parameters and isometric knee flexor muscle strength (IKFS) in healthy individuals. IKFS was measured for twenty participants (22.15±2.41 y.o; 8 females, 12 males) by a hand-held dynamometer. Investigated parameters were total and individual cross-sectional areas (CSA), Muscle-Thickness (MT), and pennation-angle (PA) for Biceps Femoris-long head (LBF), Semitendinosus (ST) and Semimembranosus (SM) muscles at 25%, 50% and 75% length of the thigh.

Detailed Description
-----------------
The images of hamstring muscles were taken by a US device (Toshiba Aplio 500, Japan) with a linear probe (10-12 MHz, with a footprint of 52 mm). For each participant, maximum voluntary IKFS was measured from the non-dominant side in the prone position with foot and ankle stayed outside of the bed. Maximum IKFS (20 limbs) was measured by an HHD (A Lafayette Model 01165) (Lafayette, IN) at 15° knee flexion in prone lying position

Official Title
-----------------
Investigation of the Correlation Between Ultrasonography Based Muscle Architecture Parameters and Maximum Voluntary Isometric Knee Flexor Muscle Strength

Conditions
-----------------
Ultrasound Imaging

Intervention / Treatment
-----------------
* Other: muscle strength and ultrasound imaging measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: being healthy young Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 28 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: muscle strength and ultrasound imaging measurement|hamstring muscle strenght measured by hand held dynamometer. The long head of Biceps Femoris, Semitendinosus, Semimembronosus were evaluated by B-mode ultrasound imaging.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The association between IKFS and ultrasound-based muscle architecture in this study will investigate potential relations of ultrasound-based muscle architecture parameters and isometric knee flexor muscle strength (IKFS) in healthy individuals. | IKFS was measured for twenty participants by a hand-held dynamometer. Investigated parameters were total and individual cross-sectional areas (CSA), Muscle-Thickness (MT), and pennation-angle (PA) for Biceps Femoris-long head (LBF), Semitendinosus (ST) and Semimembranosus (SM) muscles at 25%, 50% and 75% length of the thigh. The association between IKFS and ultrasound-based muscle architecture parameters was assessed. | an average of 1 year |
Polymorphonuclear Cells' Sensitivity to Aggregatibacter Actinomycetemcomitans Bacteria in Patients With Aggressive Periodontitis

Study Overview
=================
Brief Summary
-----------------
aggressive periodontitis is an inflammatory disease which damage the teeth supporting structures mostly in young patients. and has genetic basis. a specific bacteria: Aggregatibacter actinomycetemcomitans (Aa) is associated with this disease, and found to damage leukocytes by using a specific leukotoxin. in the research the investigators are aiming to find molecular and immunological basis to aggressive periodontitis.

Conditions
-----------------
Periodontal Disease

Intervention / Treatment
-----------------
* Other: blood extraction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients in periodontal department healthy diagnosed with chronic/aggressive periodontal disease interested in participating the research Exclusion Criteria: diagnosed with diabetes, heart disease, immunosuppression, thrombocytopenia, clotting enzyme deficiency. using alcohol, or drugs pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: aggressive periodontitis<br>25 patients with aggressive periodontitis blood extraction | Other: blood extraction<br>* 6 ml blood extraction from each patients in all 3 arms of the study<br>|
| Experimental: chronic periodontitis<br>25 patients with chronic periodontitis blood extraction | Other: blood extraction<br>* 6 ml blood extraction from each patients in all 3 arms of the study<br>|
| Experimental: healthy<br>25 healthy periodontal patients blood extraction | Other: blood extraction<br>* 6 ml blood extraction from each patients in all 3 arms of the study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| flow cytometry | the investigators use flow cytometry technique in order to determine the influence of gingival bacteria on the leukocytes, after culturing the two together. | 12 hours after blood extraction | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| microscopy observation | the investigators use microscopy in order to determine the influence of gingival bacteria on the leukocytes, after culturing the two together | 12 hours after blood extraction |
Comparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess treatment responses comparing a newly FDA-approved PEG laxative versus placebo.

Official Title
-----------------
Comparison of Braintree PolyethyleneGlycol(PEG) Laxative and Placebo for Relief of Constipation From Constipating Medications

Conditions
-----------------
Constipation

Intervention / Treatment
-----------------
* Drug: polyethyleneglycol3350


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult male or female ambulatory outpatient age 19 or older. Patients meet ROME II Criteria Patients not meeting ROME IBS criteria Use of a constipating medication (>= 3% in PDR) If female and of childbearing potential, patient must be surgically sterilized or using oral contraceptives, depot contraceptives, intrauterine device, or testifies that she is monogamous with a vasectomized partner, or practices abstinence and will continue to do so during the duration of study Written informed consent. Exclusion Criteria: Known or suspected obstruction, gastric retention, ileus, perforation, fecal impaction or inflammatory bowel disease. Prior small bowel or colonic resection or colostomy. Weight < 80 lbs. Unwilling or unable to undergo any colon diagnostic examinations at the end of the study if not performed within 5 years of the informed consent date advised by clinically accepted indications. Positive stool hemoccult. Significant cardiac, renal or hepatic insufficiency. Pregnant or expecting to become pregnant within 120 days of study enrollment. Lactating or breast feeding. Subjects who in the opinion of the investigator would be unable to comply adequately with the study plan. Use of investigational drugs in the last 30 days. Patients with known allergy to PEG or PEG medications such as PEG or sulfate-free electrolyte lavage solutions

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: polyethyleneglycol3350|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A successful outcome is defined as no longer meeting the definition of constipation using ROME I criteria |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis of individual ROME I criteria |  |  | 
| Safety (adverse event and laboratory testing) |  |  |
Somatuline Predictive Factors in Acromegaly and NET

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to identify predictive factors for the response to Lanreotide treatment in Acromegaly as well as in Neuroendocrine Tumours.

Official Title
-----------------
Non-interventional, Observational Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel® (ATG) Treatment in Subjects With Either Acromegaly or Neuroendocrine Tumours (NET)

Conditions
-----------------
Acromegaly, Neuroendocrine Tumours

Intervention / Treatment
-----------------
* Drug: Somatuline Autogel® 60, 90 or 120 mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent (also mandatory in case of retrospective documentation of subject data) Diagnosis of acromegaly or NET with the intention to be treated with ATG or already on treatment with ATG Exclusion Criteria: The subject has already been included in this study Participation in an interventional trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neuroendocrine Tumours<br>The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations. | Drug: Somatuline Autogel® 60, 90 or 120 mg<br> <br> |
| Acromegaly<br>The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations. | Drug: Somatuline Autogel® 60, 90 or 120 mg<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in biochemical markers (Growth Hormone [GH] & Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects) |  | Baseline and 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in biochemical markers (Growth Hormone [GH] & Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects) |  | Baseline and 2 years |
FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to compare the two imaging modalities perfusion weighted MR-imaging and FET-PET in their ability to provide an accurate histological evaluation of low grade glioma and to reveal focal abnormalities within a homogeneously appearing tumor. Additionally, therapeutic effects should be assessed during a time period of two years.

Official Title
-----------------
Molecular Correlates and Clinical Significance of Positron Emission Tomography With FET-PET in Combination With Perfusion-weighted Magnetic Resonance Imaging (PWI) in Patients With Low Grade Gliomas

Conditions
-----------------
Astrocytoma, Oligoastrocytoma, Oligodendroglioma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: neuroradiologically suspected low grade glioma (Astrocytoma WHOI-II, Oligodendroglioma WHO II, Oligoastrocytoma WHO II) histological verification will be obtained either by microsurgery or by stereotactic biopsy patients older than 18 years Karnofsky Performance Score >=70 pregnant or nursing female patients will not be included in this study Exclusion Criteria: patients in whom informed consent cannot be obtained due to organic brain syndrome or insufficient language skills patients who cannot lie quiet for a time period of app. two hours during the FET-PEt scan medical history of a metastatic brain disease patients in whom an MRI scan cannot be performed due to claustrophobia metallic protheses or pacemakers etc.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A<br>Patients with a suspected WHO II low grade glioma, disease progression within 1 year | |
| Group B<br>Patients with a suspected WHO II low grade glioma, progression free within 1 year | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression Free survival |  | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Low grade glioma, Astrocytoma, Molecular imaging, FET PET, Therapy monitoring, Temodar
Pilot Trial of Chlorhexidine Gluconate (CHG) Preoperative Skin Preparation

Study Overview
=================
Brief Summary
-----------------
Pilot study to evaluate and compare activity of CHG preoperative preparation with comparator CHG

Detailed Description
-----------------
Evaluate and compare similar preoperative surgical preparations in healthy volunteers. Efficacy was assess using Tentative Final Monograph (TFM) criteria.

Official Title
-----------------
Pilot Trial Assessment of the Antimicrobial Efficacy of Medline 2% CHG Cloth Preoperative Skin Preparation

Conditions
-----------------
Surgery

Intervention / Treatment
-----------------
* Drug: CHG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy No dermatological conditions Exclusion Criteria: Sensitivity to CHG Sensitivity to natural latex rubber or adhesive skin products

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CHG Cloth<br>3 min application time | Drug: CHG<br>* Single application<br>* Other names: Chlorhexidine Gluconate;|
| Active Comparator: Comparator CHG<br>Marketed 2% CHG | Drug: CHG<br>* Single application<br>* Other names: Chlorhexidine Gluconate;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Log Change in Bacterial Flora on Abdomen and Groin | Change was calculated as the baseline time point minus the later time points over an 8 hour period. | 10 min, 6 hr and 8 hr | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Preoperative surgical skin preparation
Bariatric Surgery and Pharmacokinetics of Buprenorphine

Study Overview
=================
Brief Summary
-----------------
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on buprenorphine are investigated.

Official Title
-----------------
Bariatric Surgery and Pharmacokinetics Buprenorphine: BAR-MEDS Buprenorphine

Conditions
-----------------
Obesity, Morbid

Intervention / Treatment
-----------------
* Drug: Buprenorphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway Being a Norwegian citizen Exclusion Criteria: Having previously undergone resections in the GI-tract

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Buprenorphine|Patients are tested for their normal prescription buprenorphine medication|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Buprenorphine concentration in blood serum (area under curve (AUC)) |  | From baseline to 1 year postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bariatric surgery, Gastrointestinal tract, Biological availability, Pharmacokinetics, Buprenorphine